CTSO Key Statistics, Chart & Performance
The current stock price of CTSO is 0.67 USD. In the past month the price decreased by -9.91%. In the past year, price decreased by -29%.
CTSO Latest News, Press Relases and Analysis
CTSO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.73 | 223.28B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.06 | 207.74B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.91 | 143.92B | ||
| SYK | STRYKER CORP | 27.28 | 137.40B | ||
| BDX | BECTON DICKINSON AND CO | 14.08 | 57.93B | ||
| IDXX | IDEXX LABORATORIES INC | 55.06 | 55.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.43 | 49.86B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.87 | 39.46B | ||
| RMD | RESMED INC | 25.12 | 36.30B | ||
| DXCM | DEXCOM INC | 37.53 | 27.23B | ||
| PODD | INSULET CORP | 63.3 | 20.35B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.61 | 18.61B |
Related stock screener links
About CTSO
Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Company Info
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852 US
CEO: Phillip P. Chan
Employees: 149
Phone: 19733298885
CYTOSORBENTS CORP / CTSO FAQ
What does CTSO do?
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
What is the stock price of CYTOSORBENTS CORP today?
The current stock price of CTSO is 0.67 USD.
Does CYTOSORBENTS CORP pay dividends?
CTSO does not pay a dividend.
How is the ChartMill rating for CYTOSORBENTS CORP?
CTSO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is CYTOSORBENTS CORP (CTSO) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CTSO.
Can you provide the number of employees for CYTOSORBENTS CORP?
CYTOSORBENTS CORP (CTSO) currently has 149 employees.
CTSO Technical Analysis
CTSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTSO. CTSO may be in some trouble as it scores bad on both profitability and health.
CTSO Financial Highlights
Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS increased by 51.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.14% | ||
| ROE | -117.35% | ||
| Debt/Equity | 1.61 |
CTSO Forecast & Estimates
8 analysts have analysed CTSO and the average price target is 5.48 USD. This implies a price increase of 718.28% is expected in the next year compared to the current price of 0.67.
For the next year, analysts expect an EPS growth of 59.74% and a revenue growth -3.82% for CTSO